Interview with Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States. (10:44)Download Aducanumab’s price can inform the drug-pricing policy debate because it responds to key features of the market environment for physician-administered drugs: Medicare’s reimbursement formula, payment to physicians for infused drugs, and cost-sharing requirements.
No takes yet. Share an insight, caveat, or question.
James C. Robinson (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: